MEDICAL POLICY

SUBJECT: INFLAMMATORY MARKERS OF CORONARY ARTERY DISEASE RISK	**EFFECTIVE DATE: 12/18/02** **REVISED DATE: 05/21/03, 05/19/04, 03/17/05, 01/19/06, 11/16/06, 09/20/07, 09/18/08, 02/19/09, 03/18/10, 04/21/11, 04/19/12, 04/18/13, 04/17/14, 04/16/15, 06/16/16, 7/20/17, 06/21/18**
POLICY NUMBER: 2.02.15	
CATEGORY: Laboratory Tests	**PAGE: 1 OF: 8**

- *If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.*
- *If a commercial product (including an Essential Plan product) or a Medicaid product covers a specific service, medical policy criteria apply to the benefit.*
- *If a Medicare product covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.*

POLICY STATEMENT:

I.   Based on our assessment of the peer-reviewed literature, including the January 2003 recommendation put forth by the American Heart Association and Centers for Disease Control and Prevention, the use of *high sensitivity C-reactive protein (hs-CRP)*testing for primary prevention in the clinical setting is considered **medically necessary** for those individuals who are at intermediate risk (10% - 20%) of heart disease over the next ten years by conventional risk scoring (e.g., Framingham Heart Study criteria). Individuals must be free of non-cardiac conditions that are known to increase CRP (e.g., rheumatoid arthritis, chronic inflammatory processes).

II. Based on our assessment of the peer-reviewed literature, all other indications for *hs-CRP* testing, aside from the indication above, are considered **not medically necessary**.

III. Based on our criteria and review of the peer-reviewed literature, measurement of other inflammatory markers, including but not limited to, *lipoprotein-associated phospholipase A_2 (Lp-PLA$_2$),* or *plasma myeloperoxidase (MPO)* in the assessment of cardiovascular risk has not been proven to improve health outcomes and is considered **investigational**.

Refer to Corporate Medical Policy #2.02.29 Cardiovascular Disease Risk Assessment - Laboratory Evaluation of Lipids.

Refer to Corporate Medical Policy #11.01.03 regarding Experimental or Investigational Services.

POLICY GUIDELINES:

I.   In order to be eligible for coverage of hs-CRP testing, the patient must be categorized as at a 10–20% higher risk (intermediate risk) than the average individual. Determination of increased risk is based on the Framingham Heart Study which identified patients who can be classified as either low, intermediate, or high risk for the cardiovascular events in the next ten years. The classification is based on factors such as, high blood pressure, high blood cholesterol, smoking, obesity, diabetes, and physical inactivity.

II. The Federal Employees Health Benefit Program (FEHBP/FEP) requires that procedures, devices or laboratory tests approved by the U.S. Food and Drug Administration (FDA) may not be considered investigational and thus these procedures, devices or laboratory tests may be assessed only on the basis of their medical necessity.

DESCRIPTION:

High sensitivity C-reactive protein (hs-CRP) is a nonspecific acute phase reactant produced by the liver as a marker of inflammatory processes. Traditionally CRP has been used to monitor inflammatory processes, such as infections or autoimmune diseases. Chronic inflammatory disorders, including autoimmune diseases and malignancies can produce persistent increases in serum CRP concentrations. Studies suggest the association of low-level chronic inflammation during atherogenesis. The use of technologies collectively known as high-sensitivity CRP (hs-CRP) including enzyme linked immunoabsorbent assays (ELISA) and other techniques using monoclonal antibodies has allowed for a greater precision in detecting the lower levels of CRP related to chronic inflammation in otherwise healthy individuals. Results from studies indicate a correlation between hs-CRP levels and coronary artery disease. It is theorized that the increased sensitivity of high-sensitivity CRP (hs-CRP) test should be able to detect that activity as a marker for cardiovascular disease, either current or future.

Lipoprotein-associated phospholipase A_2 (Lp-PLA$_2$), also known as platelet-activating factor acetylhydrolase, is an enzyme that hydrolyses phospholipids and is primarily associated with low-density lipoproteins. Accumulating evidence has suggested that Lp-PLA$_2$ is a biomarker of coronary artery disease and may have a proinflammatory role in the progression of atherosclerosis. The recognition that atherosclerosis represents, in part, an inflammatory process has created considerable interest in measurement of proinflammatory factors as part of cardiovascular disease risk assessment.

Plasma myeloperoxidase (MPO), an abundant leukocyte enzyme, is elevated in culprit lesions that have fissured or ruptured in patients with sudden death from cardiac causes. Research suggests a mechanistic link between myeloperoxidase and both inflammation and cardiovascular disease risk. It has been proposed that elevated plasma MPO levels may be an independent predictor of endothelial dysfunction, angiographically evident CAD and cardiac risk.

RATIONALE:

Several of the high-sensitivity C-reactive protein tests have received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA). In 2003, the FDA cleared for marketing an enzyme linked immunoabsorbent (ELISA) test, the PLAC test (diaDexus, San Francisco, CA) to measure levels of Lp-PLA$_2$.

Use of hs-CRP in Primary Prevention of Cardiovascular Disease:
Several prospective epidemiologic studies have suggested that the measurement of hs-CRP may be an independent risk factor for cardiovascular disease.

Use of hs-CRP in Secondary Prevention of Cardiovascular Disease:
Currently no clinical studies have evaluated how knowledge of hs-CRP levels should influence current management strategies, such as diet, weight control, or cholesterol-lowering therapies in patients with cardiovascular disease and whether such management changes would reduce the subsequent incidence of future cardiovascular events.

Scientific evidence supports the theory that hs-CRP is a strong and independent marker for future heart events in patients who have already been assessed to be at 10 - 20% greater risk than the average individual. Based on this information, use of the hs-CRP test to further evaluate this group of patients may result in a change in treatment and/or lifestyles that could decrease the risk for future cardiac events.

No clinical trials have been completed in which a population has been randomly allocated to hs-CRP screening compared with a control population group not allocated to hs-CRP screening and both groups followed up prospectively to determine the benefits and harms of the screening.

Recommendation of AHA/CDC (American Heart Association/Centers for Disease Control) regarding the role of hs-CRP measurements in clinical practice (2003): The strongest recommendation by the CHD/AHA suggests that the results of hs-CRP may help identify patients at intermediate risk (10%-20% risk of CHD per 10 years) who may benefit from primary prevention of CVD. It is estimated that some 30%-40% of the population may fall into this intermediate risk group. If the results of the hs-CRP measurement are considered high, patients may then be offered various interventions, frequently including the initiation of statin therapy. Therefore, the use of hs-CRP as one component of a risk assessment tool may ultimately result in considerably more patients being placed on lifelong drug therapy.

Ridker PM, et al. conducted a randomized double-blind, placebo controlled, multicenter study (the Jupiter Trial) which investigated whether treatment with Rosuvastatin, 20 mg daily, as compared with placebo, would decrease the rate of first major cardiovascular events for healthy men and women with elevated high-sensitivity C-reactive protein levels, a calculated Framingham risk score of 10% or less, or an LDL cholesterol level of 100 mg per deciliter (2.6 mmol per liter) or lower. The observed relative reductions in the hazard ratio associated with rosuvastatin for the primary end point were similar to those in higher-risk groups. For subjects with elevated high-sensitivity C-reactive protein levels but no other major risk factor other than increased age, the benefit of rosuvastatin was similar to that for higher-risk subjects (hazard ratio, 0.63; 95% CI, 0.44 to 0.92; P=0.01). Consequently, those individuals who are considered low to intermediate risk (0–20%) of heart disease but with an elevated hs-CRP measurement may also benefit from statin

therapy. While this study shows benefits of statin therapy, it does not address the clinical value of hs-CRP testing for individuals with low cardiovascular risk. The study was prematurely terminated before the long-term safety and efficacy of the drug therapy could be established. In addition, those patients treated with rosuvastatin demonstrated significantly higher glycated hemoglobin levels and incidence of diabetes. Further long-term studies are needed to determine the role of hs-CRP testing in clinical management of individual with low cardiovascular risk.

Lipoprotein-associated phospholipase A$_2$ (Lp-PLA$_2$.). Current studies generally report the utility of Lp-PLA2 as an independent biomarker for coronary artery disease and recurrent cardiac events. However, Lp-PLA2 was not found to be an independent marker for subclinical atherosclerosis, and a study of the ARIC (Atherosclerosis Risk in Communities) cohort found that routine measurement of Lp-PLA2 did not improve existing risk stratification models that use traditional risk factors. Interventional studies involving Lp-PLA2 suggest that the level of Lp-PLA2 is modifiable by antihyperlipidemics. An ad hoc study of the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy - Thombolysis In Myocardial Infarction) trial concluded that the 30-day Lp-PLA2 level was independently associated with an increased risk of cardiovascular events. Another ad hoc study from the DIACOR (Diabetes and Combined Lipid Therapy Regimen) trial demonstrated improved Lp-PLA2 levels compared to baseline, with no difference found between treatment groups among 300 patients with diabetes and mixed dyslipidemias randomized to either fenofibrate, simvastatin or both for 12 weeks.

Results of two large-scale observational studies have suggested that Lp-PLA$_2$ is an independent risk factor for coronary heart disease in men. However, the key outcome of cardiac risk assessment is an improvement in health outcomes. Improved risk prediction does not by itself result in improved health outcomes. To improve outcomes, clinicians must have the tools to translate this information into clinical practice. To do this requires guidelines that incorporate emerging risk factors into existing risk prediction models and that have been demonstrated to classify patients into risk categories with greater accuracy. Predictive models also need to be accompanied by treatment guidelines that target intervention toward patients who will get the most benefit. At present, measurements of Lp-PLA$_2$ are not a component of the guidelines developed by the National Cholesterol Education Program Adult Treatment Panel III.

While studies have suggested that statin drugs and fibrates may reduce levels of Lp-PLA$_2$, it is not known whether such drug therapy in patients not already considered candidates based on other well established risk factors would ultimately decrease the incidence of coronary heart disease. Although results of studies of Lp-PLA$_2$ test are promising, its biological role is not yet understood, its ability to improve on existing risk stratification methods is uncertain, and its clinical utility remains in question, particularly when compared to currently available methods for cardiovascular risk reduction. The extent to which antihyperlipidemics modify the level of Lp-PLA$_2$ beyond their established therapeutic use, and therefore alter cardiac outcomes, is unknown.

Risk prediction for stroke. While some studies have shown that levels of both Lp-PLA$_2$ and C-reactive protein were higher in stroke cases, improved risk prediction does not necessarily result in improved outcomes. Results of studies have not been incorporated into clinical management.

Currently, PrognostiX Inc. (Cleveland Clinic, Cleveland, Ohio), is the only company to have an FDA approved ELISA test kit for plasma MPO concentration. The product is known as CardioMPO and is intended for use in conjunction with clinical history, ECG and cardiac biomarkers to evaluate patients that present with chest pain. It operates using the sandwich ELISA method.

Several studies have assessed the value of plasma myeloperoxidase (MPO) as a predictor of the risk of cardiovascular events in patients presenting with chest pain (Brennan, 2003) or acute coronary syndrome and chronic heart failure. MPO levels have also been evaluated as an inflammatory marker of future coronary artery disease (CAD) in apparently healthy individuals (Meuwesem, et al. 2007). Although studies of MPO testing indicate a possible relationship between elevated levels and cardiac risk, its ability to improve on existing risk stratification methods is unclear. Results of studies have not been incorporated into clinical management.

CODES: Number   Description

Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract.

CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.

Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.

Code Key: Experimental/Investigational = (E/I), Not medically necessary/ appropriate = (NMN).

CPT: 83698 **(E/I)**   Lipoprotein-associated phospholipase A_2, (Lp-PLA$_2$)

83876 **(E/I)**   Myeloperoxidase (MPO)

86141   High sensitivity, C-reactive protein (hs-CRP)

0052U **(E/I)**   Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation (VAP Cholesterol Test by VAP Diagnostics Laboratory, Inc)

Copyright © 2018 American Medical Association, Chicago, IL

HCPCS: No specific code(s)

ICD10:
Code	Description
E71.30	Disorder of fatty-acid metabolism, unspecified
E75.21	Fabry (-Anderson) disease
E75.22	Gaucher disease
E75.240-E75.249	Niemann-Pick disease (code range)
E75.3	Sphingolipidosis, unspecified
E75.5	Other lipid storage disorders
E75.6	Lipid storage disorder, unspecified
E77.0-E77.9	Disorders of glycoprotein metabolism (code range)
E78.0-E78.9	Disorders of lipoprotein metabolism and other lipidemias (code range)
E88.1-E88.2	Lipodystrophy or Lipomatosis, not elsewhere classified (code range)
E88.89	Other specified metabolic disorders
I20.0-I20.9	Angina pectoris (code range)
I21.01-I22.1	ST elevation (STEMI) myocardial infarction of anterior or inferior wall (code range)
I24.1	Dressler's syndrome
I25.110-I25.119	Atherosclerotic heart disease of native coronary artery (code range)
I25.2	Old myocardial infarction
I25.700-I25.799	Atherosclerosis of coronary artery bypass graft(s) and coronary artery of transplanted heart with angina pectoris (code range)
I70.0	Atherosclerosis of aorta

I70.1	Atherosclerosis of renal artery
Z82.41	Family history of sudden cardiac death
Z82.49	Family history of ischemic heart disease and other diseases of the circulatory system
Z86.711	Personal history of pulmonary embolism
Z86.718	Personal history of other venous thrombosis and embolism
Z86.72	Personal history of thrombophlebitis
Z86.73	Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits
Z86.74	Personal history of sudden cardiac arrest
Z86.79	Personal history of other diseases of the circulatory system

REFERENCES:

*Abd TT, et al. The role of C-reactive protein as a risk predictor of coronary atherosclerosis: implications from the JUPITER trial. Curr Atheroscler Rep 2011 Apr;13(2):154-61.

*Alvarez GB, et al. High-sensitivity C-reactive protein in high-grade carotid stenosis: risk marker for unstable carotid plaque. J Vasc Surg 2003 Nov;38(5):1018-24.

*Aviles RJ, et al. Inflammation as a risk for atrial fibrillation Circ 2003 Dec 16;108(24):3006-10.

*Baldus S, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circ 2003 Sep 23;108(12):1440-5.

*Ballantyne CM, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study. Circ 2004 Feb 24;109(7):837-42.

*Bhatti S, et al. Lp-PLA2 as a marker of cardiovascular diseases. Curr Atheroscler Rep 2010;12:140–4.

*Blake GJ, et al. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 2001 Nov;38(5):1302-6.

Blue Cross Blue Shield Association. High sensitivity C-reactive protein. Medical Policy Reference Manual Policy #2.04.22. 2011 Sep 01.

*BlueCross BlueShield Association. Measurement of lipoprotein-associated phospholipase A_2 (Lp-PLA$_2$) in the assessment of cardiovascular risk. Medical Policy Reference Manual Policy #2.04.32. 2017 Dec 14.

BlueCross BlueShield Association. Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease. Medical Policy Reference Manual Policy #2.04.65. 2018 Feb 02.

*BlueCross BlueShield Association Technology Evaluation Center (TEC). Special report: C-reactive protein for risk stratification in coronary heart disease screening. 2003 May.

*Brennan M, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003 Oct 23;349(17):1595-604.

*Chang C, et al. The myeloperoxidase -463G/A polymorphism and coronary artery disease risk: A meta-analysis of 1938 cases and 1990 controls. Clin Biochem 2013;46(16-17):1644-8.

*Cook NR ,et al. Clinical utility of lipoprotein-associated phospholipase A2 for cardiovascular disease prediction in a multiethnic cohort of women. Clin Chem 2012 Sep;58(9):1352-63.

*Elkind MS, et al. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 2006 Oct 23;166(19):2073-80.

*Epps KC, et al. Lp-PLA2 – a novel risk factor for high-risk coronary and carotid artery disease. J Intern Med 2011;269:94–106.

*Folsom AR, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers; the atherosclerosis risk in communities study. Arch Intern Med 2006 Jul 10;166(13):1368-73.

Garg PK, et al. Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: the multi-ethnic study of atherosclerosis. Atherosclerosis 2015 Jul;241(1):176-82.

Garg PK, et al. Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease in a multi-ethnic cohort: the multi-ethnic study of atherosclerosis. Vasc Med 2017 Feb;22(1):5-12.

Gregson J, et al. Variation of lipoprotein associated phospholipase A2 across demographic characteristics and cardiovascular risk factors: a systematic review of the literature. Atherosclerosis 2012 Nov;225(1):11-21.

*Grundy SM, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circ 2004 Jul 13;110(2):227-39.

*Grundy SM, et al. Prevention conference V beyond secondary prevention: identifying the high-risk patient for primary prevention: medical office assessment: writing group I. Circ 2000:1010:e3.

Han L, et al. Prognostic value of lipoprotein-associated phospholipase A2 mass for all-cause mortality and vascular events within one year after acute ischemic stroke.Atherosclerosis 2017 Nov;266:1-7.

*Hatoum IJ, et al. Lipoprotein-associated phospholipase A2 activity improves risk discrimination of incident coronary heart disease among women. Am Heart J 2011;161:516-22.

*Kardys I, et al. Lipoprotein-associated phospholipase A2 and measures of extra atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol 2006 Mar;26(3):631-6.

Kataoka Y, et al. Myeloperoxidase levels predict accelerated progression of coronary atherosclerosis in diabetic patients: insights from intravascular ultrasound. Atherosclerosis 2014 Feb;232(2):377-83.

*Koenig W, et al. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circ 2004 Mar 23;109(11):1349-53.

*Koenig W, et al. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circ 2004 Oct 5;110(14):1903-8.

*Koenig W, et al. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 2006 Jul;26(7):1586-93.

*Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int J Cardiol 2013 Oct 15;168(6):5126-34.

Li D, et al. Lipoprotein-associated phospholipase A1 and risk of coronary heart disease and ischemic stroke in the general population: a systematic review and meta-analysis. Clin Chim Acta 2017 May 14;471:38-45.

*Lin J, et al. Association of Lp-PLA2-A and early recurrence of vascular events after TIA and minor stroke. Neurology 2015 Nov 3;85(18):1585-91.

*Liu J, et al. Association between the lipoprotein-associated phospholipase A2 activity and the progression of subclinical atherosclerosis. J Atheroscler Thromb 2014;21(6):532-42.

Maiolino G, et al. Lip0oprotein-assocaited phospholipase A2 prognostic role in atherosclerotic complications. World J Cardiol 2015 Oct 26;7(10):609-20.

*Mangili A, et al. Lipoprotein-associated phospholipase a2, a novel cardiovascular inflammatory marker, in HIV-infected patients. Clin Infect Dis 2014 Mar;58(6):893-900.

*Muhlestein JB, et al. The reduction of inflammatory biomarkers by statin, fibrate, and d combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol 2006 Jul 18;48(2):396-401.

*O'Donoghue M, et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastin Or atorVastin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circ 2006 Apr 11;113(14):1745-52.

*Pai JK, et al. Inflammatory markers and the risk of coronary heart disease in men and women. NEJM 2004 Dec 16;351(25):2599-610.

*Pearson TA, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circ 2003 Jan 23;107(3):499-511.

*Ridker PM, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circ 2003 Jan 28;107(3):391-7.

*Ridker, PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circ 2003 Jan 28;107(3):363-9.

Risk Assessment Tool for estimating 10-year CVD risk. [http://professional.heart.org/professional/GuidelinesStatements/PreventionGuidelines/UCM_457698_Prevention-Guidelines.jsp] accessed 5/15/18.

*Tang WH, et al. Plasma myeloperoxidase levels in patients with chronic heart failure. Am J Cardiol 2006 Sep 15;98(6):796-9.

Talmud PJ, et al. Deciphering the causal role of sPLA2s and Lp-PLA2 in coronary heart disease. Arterioscler Thromb Vasc Biol 2015 Nov;35(11):2281-9.

Tian Y, et al. The associations of stroke, transient ischemic attack, and/or stroke-related recurrent vascular events with lipoprotein-associated phospholipase A2. Medicine (Baltimore) 2017 Dec;96(51):e9413.

*Vasan RS, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circ 2003 Mar 25;107(11):1486-91.

*Yeh ETH, et al. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circ 2003 Jan 28;107(3):370-2.

Younus A, et al. Lipoprotein-associated phospholipase A2 and its relationship with markers of subclinical cardiovascular disease: a systematic review. J Clin Lipidol 2017 Mar-apr;11(2):328-337.

Zheng D, et al. Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement. Lipids Health Dis 2014 Mar 1;13:41.

*key articles

KEY WORDS:

Cardiac disease risk, CRP, hs-CRP, Lp-PLA2, PLAC test, plasma myeloperoxidase (MPO).

CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS

There is currently no National (NCD) or Local Coverage Determination (LCD) for High Sensitivity C-Reactive Protein Testing (hsCRP) and Lipid Testing.